Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

188.40 -4.59 (-2.38%)
Streaming Delayed Price Updated: 3:46 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
 
Via Benzinga
Krystal Biotech Stock Sees RS Rating Jump To 91
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
KKR and GoDaddy also will join before the open on June 24. 
Via Investor's Business Daily
Topics Stocks
How Is The Market Feeling About Krystal Biotech?
 
Via Benzinga
(KRYS) - Analyzing Krystal Biotech's Short Interest
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today
 
Via Benzinga
KRYS Stock Earnings: Krystal Biotech Beats EPS, Misses Revenue for Q1 2024
KRYS stock results show that Krystal Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 Today
 
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) is a Leading Gainer in 2/26 Morning Trading
Via Investor Brand Network
A Preview Of Krystal Biotech's Earnings
 
Via Benzinga
Expert Ratings for Krystal Biotech
 
Via Benzinga
Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results
Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday. 
Via Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Have investors already missed the boat with this stock? 
Via The Motley Fool
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
A Preview Of Krystal Biotech's Earnings
 
Via Benzinga
5 Analysts Have This to Say About Krystal Biotech
 
Via Benzinga
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
5 Analysts Have This to Say About Krystal Biotech
 
Via Benzinga
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.